BG104368A - Novel polymorphic forms of cipamfylline - Google Patents

Novel polymorphic forms of cipamfylline

Info

Publication number
BG104368A
BG104368A BG104368A BG10436800A BG104368A BG 104368 A BG104368 A BG 104368A BG 104368 A BG104368 A BG 104368A BG 10436800 A BG10436800 A BG 10436800A BG 104368 A BG104368 A BG 104368A
Authority
BG
Bulgaria
Prior art keywords
cipamfylline
polymorphic forms
novel polymorphic
forms
novel
Prior art date
Application number
BG104368A
Other languages
Bulgarian (bg)
English (en)
Inventor
Drake Eggleston
Ian R. Lynch
Original Assignee
Smithkline Beecham Corporation
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation, Smithkline Beecham P.L.C. filed Critical Smithkline Beecham Corporation
Publication of BG104368A publication Critical patent/BG104368A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BG104368A 1997-10-23 2000-04-21 Novel polymorphic forms of cipamfylline BG104368A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6323897P 1997-10-23 1997-10-23
PCT/US1998/022451 WO1999020625A1 (en) 1997-10-23 1998-10-23 Novel polymorphic forms of cipamfylline

Publications (1)

Publication Number Publication Date
BG104368A true BG104368A (en) 2001-02-28

Family

ID=22047900

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104368A BG104368A (en) 1997-10-23 2000-04-21 Novel polymorphic forms of cipamfylline

Country Status (28)

Country Link
US (2) US6583283B1 (es)
EP (1) EP1025103A4 (es)
JP (1) JP2001520228A (es)
KR (1) KR20010031246A (es)
CN (1) CN1280579A (es)
AP (1) AP2000001793A0 (es)
AR (1) AR015190A1 (es)
AU (1) AU751561B2 (es)
BG (1) BG104368A (es)
BR (1) BR9814099A (es)
CA (1) CA2306980A1 (es)
CO (1) CO4990930A1 (es)
DZ (1) DZ2629A1 (es)
EA (1) EA003445B1 (es)
HU (1) HUP0100019A3 (es)
ID (1) ID23885A (es)
IL (1) IL135711A0 (es)
MA (1) MA24682A1 (es)
NO (1) NO20002012D0 (es)
NZ (1) NZ504051A (es)
PE (1) PE122599A1 (es)
PL (1) PL340257A1 (es)
SA (1) SA99191117A (es)
SK (1) SK5642000A3 (es)
TR (1) TR200001109T2 (es)
UY (2) UY25220A1 (es)
WO (1) WO1999020625A1 (es)
ZA (1) ZA989622B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
EP1355907A1 (en) 2001-01-31 2003-10-29 Pfizer Products Inc. Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of pde4 isozymes
KR20030070150A (ko) 2001-01-31 2003-08-27 화이자 프로덕츠 인크. Pde4 이소자임 억제제로서 유용한 에테르 유도체
EE200300360A (et) 2001-01-31 2003-12-15 Pfizer Products Inc. PDE4 isosüümide inhibiitoritena kasutatavad nikotiinamiidi biarüülderivaadid
EP1509524B1 (en) * 2002-05-31 2008-03-26 Schering Corporation Xanthine phosphodiesterase v inhibitor polymorphs
US7585859B2 (en) 2004-05-06 2009-09-08 Plexxikon, Inc. PDE4B inhibitors and uses therefor
EP1786813A2 (en) 2004-09-03 2007-05-23 Plexxikon, Inc. Bicyclic heteroaryl pde4b inhibitors
EP1951235B1 (en) * 2005-09-20 2010-03-10 Scinopharm Singapore Pte, Ltd. Novel crystal forms of irinotecan hydrochloride

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
GB9020921D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
ZA989622B (en) 1999-04-23
AP2000001793A0 (en) 2000-06-30
MA24682A1 (fr) 1999-07-01
EA200000448A1 (ru) 2000-10-30
IL135711A0 (en) 2001-05-20
ID23885A (id) 2000-05-25
HUP0100019A2 (hu) 2002-01-28
EP1025103A4 (en) 2001-11-14
EP1025103A1 (en) 2000-08-09
CA2306980A1 (en) 1999-04-29
UY25220A1 (es) 2001-08-27
KR20010031246A (ko) 2001-04-16
WO1999020625A1 (en) 1999-04-29
AR015190A1 (es) 2001-04-18
US20020173648A1 (en) 2002-11-21
AU751561B2 (en) 2002-08-22
SK5642000A3 (en) 2000-09-12
JP2001520228A (ja) 2001-10-30
NZ504051A (en) 2003-02-28
CO4990930A1 (es) 2000-12-26
PE122599A1 (es) 2000-02-12
TR200001109T2 (tr) 2000-09-21
SA99191117A (ar) 2005-12-03
DZ2629A1 (fr) 2003-03-08
EA003445B1 (ru) 2003-06-26
UY25380A1 (es) 1999-11-17
HUP0100019A3 (en) 2003-01-28
US6583283B1 (en) 2003-06-24
NO20002012L (no) 2000-04-17
NO20002012D0 (no) 2000-04-17
CN1280579A (zh) 2001-01-17
PL340257A1 (en) 2001-01-29
AU1274499A (en) 1999-05-10
BR9814099A (pt) 2000-10-10

Similar Documents

Publication Publication Date Title
AU2160492A (en) Treatment of human diseases involving dysregulation or dysfunction of the nervous system
NZ335992A (en) Substituted pyrimidinone and pyridone compounds and methods of use
YU45204A (sh) 3-BETA-D-RIBOFURANOZILTIAZOLO/4,5-d/ PIRIMIDINSKI NUKLEOZIDII NJIHOVA UPOTREBA
CA2269815A1 (en) Thienopyrimidines having pde v-inhibiting action
NZ284846A (en) 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
WO1998024782A3 (en) Substituted pyrimidine compounds and their use
IL119461A (en) 4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
AU2002327378A1 (en) Treatment of neuropsychiatric disorders by near-diaphragmatic nerve stimulation
YU60900A (sh) Novi kristalni oblici antivirusnog benzimidazolskog jedinjenja
WO2003041643A3 (en) Hsp90-inhibiting zearalanol compounds and methods of producing and using same
AU2399892A (en) Treatment of anxiety disorders by nerve stimulation
NO20002702L (no) Tienopyrimidiner
AU4960297A (en) Bicyclic aryl carboxamides and their therapeutic use
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AU2284001A (en) Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
DE50211929D1 (en) Pyrimidinderivate
BG104368A (en) Novel polymorphic forms of cipamfylline
ZA984174B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
IL150125A0 (en) Novel compounds
ZA984177B (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases
NO991734L (no) Pyrazolinoner for behandling av potensforstyrrelser
WO2001040465A3 (en) Compositions and methods for the treatment of immune related diseases
MXPA02012260A (es) 2-aminoalquil-tieno[2,3-d]pirimidinas.
MXPA98005355A (es) Derivados de 5-[(heteroaril) alquil]-3 -oxo-pirido [1, 2-a]bencimidazol -4-carboxamida utiles en el tratamiento de trastornos del sistema nervioso central.
EP0276805A3 (en) Substituted 3-phenyl-7h-thiazoloû3,2-b¨û1,2,4¨triazin-7-ones, processes for their preparation, medicaments containing them and their use as well as some of the intermediates obtained during the preparation of said compounds